TRIUMPH-1 Phase 3 Results May 2026 marked a pivotal moment, with Eli Lilly releasing remarkable TRIUMPH-1 Phase 3 trial outcomes
SalB inhibits the angiogenic factor VEGF, which mitigates fibroblast proliferation and blood vessel infiltration, reduces tissue adhesion, and prevents epidural scarring ( 2.7 Frozen shoulder Current treatments for arthrofibrosis are limited in terms of efficacy and diversity ( SalB has been found to have anti-inflammatory and anti-fibrotic effects in the treatment of FS
Pettegrew J, Levine J, McClure R
However, both treatments share the same goal: helping patients avoid surgery, reduce dependency on medications, and regain an active, pain-free lifestyle
Patients should contact their healthcare provider if lightheadedness is severe, persistent, or worsening despite self-management strategies